MICONAZOLE 7 COMBINATION PACK
Clinical safety rating: safe
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
Miconazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and leakage of cellular contents, resulting in fungal cell death.
| Metabolism | Miconazole is primarily metabolized in the liver via oxidative pathways; the specific cytochrome P450 enzymes have not been fully characterized, but it is known to inhibit CYP2C9, CYP3A4, and CYP2C19. |
| Excretion | Miconazole is primarily metabolized in the liver, with metabolites and unchanged drug excreted in feces (50-70%) and urine (10-20%). Biliary excretion is a minor route. |
| Half-life | Terminal elimination half-life is approximately 24-30 hours after systemic absorption. Clinically, this supports once-daily dosing for the vaginal route. |
| Protein binding | Approximately 90-95% bound to serum albumin. |
| Volume of Distribution | Vd is about 20-25 L/kg, indicating extensive tissue distribution and penetration into vaginal tissues. |
| Bioavailability | Vaginal administration: systemic bioavailability is low (<1-3%) due to limited absorption through vaginal mucosa; topical absorption is negligible. |
| Onset of Action | For vaginal administration, symptomatic relief of vulvovaginal candidiasis typically begins within 24-48 hours after first dose. |
| Duration of Action | Therapeutic effect lasts for up to 7 days after completion of the 7-day vaginal regimen; clinical cure rates exceed 80%. |
| Molecular Weight | 416.13 |
Miconazole 200 mg vaginal suppository once daily at bedtime for 7 days, plus miconazole 2% cream applied intravaginally once daily at bedtime for 7 days.
| Dosage form | CREAM, SUPPOSITORY |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not recommended in pediatric patients <12 years. |
| Geriatric use | No specific dose adjustment; use caution due to increased risk of adverse effects. |
| 1st trimester | Limited human data; systemic absorption minimal with vaginal use, but avoid if possible due to lack of safety data. |
| 2nd trimester | Generally considered safe; minimal systemic absorption, unlikely to cause fetal harm. |
| 3rd trimester | Safe for use; minimal systemic absorption, no known fetal risk. |
Clinical note
Warfarin metabolism is inhibited increasing INR For topical use only not for ophthalmic use.
| FDA category | Human |
| Placental transfer | Minimal; systemic absorption is low (1-2%) after vaginal administration, resulting in negligible placental transfer. |
| Breastfeeding | Minimal systemic absorption after intravaginal application; unlikely to be excreted into breast milk in significant amounts. Compatible with breastfeeding. |
■ FDA Black Box Warning
None.
| Common Effects | vaginal yeast infections |
| Serious Effects |
Hypersensitivity to miconazole or any componentKnown allergy to imidazole antifungals
| Precautions | Hypersensitivity reactions including anaphylaxis have been reported. Discontinue if irritation or sensitization occurs. Contains mineral oil, which may cause latex products to fail. Use with caution in patients with known hypersensitivity to imidazoles. Not for oral, ophthalmic, or intravaginal administration if using topical formulation. |
| Food/Dietary | No known food interactions. Avoid alcohol as it may aggravate side effects such as dizziness or nausea, though not specific to miconazole. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Miconazole is an azole antifungal. Systemic absorption after vaginal application is minimal (approximately 1.4%). No increased risk of major birth defects has been observed in large cohort studies, although animal studies (high oral doses) show some fetotoxicity. First trimester: low risk generally accepted; second and third trimesters: safe for topical/vaginal use. Avoid high-dose systemic therapy in pregnancy. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. Monitor for local irritation or hypersensitivity. In cases of recurrent infection, rule out gestational diabetes or other immunosuppressive conditions. |
| Fertility Effects | No adverse effects on fertility reported with topical/vaginal use. Systemic high doses in animal studies showed impaired fertility, but not relevant at clinical doses for vaginal candidiasis. |
| Clinical Pearls | Miconazole 7 Combination Pack contains miconazole nitrate vaginal suppositories and external vulvar cream. Instruct patient to insert one suppository at bedtime for 7 consecutive nights, even if menstruation occurs. The external cream can be applied twice daily to relieve itching. Avoid concurrent use of latex condoms or diaphragms as the product may damage latex. Treat sexual partners only if symptomatic. |
| Patient Advice | Complete the full 7-day course even if symptoms improve. · Insert the suppository high into the vagina at bedtime. · Do not use tampons, douches, or spermicides during treatment. · Wear panty liners to protect clothing from leakage. · Avoid sexual intercourse until treatment is finished. · Apply external cream only to the vulvar area, not inside the vagina. · Discontinue and consult doctor if abdominal pain, fever, or foul-smelling discharge occurs. · If symptoms persist after treatment, seek medical evaluation. |